On September 7, 2022 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that company management will participate in the following upcoming investor conferences in September (Press release, Jounce Therapeutics, SEP 7, 2022, View Source [SID1234619170]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference: Fireside chat on Monday, September 12, 2022 at 10:00 a.m. ET in New York, NY.

Cantor Oncology, Hematology & HemeOnc Conference: Panel titled, "Tackling the Tumor Microenvironment and Further Arming the Immune System" on Wednesday, September 28, 2022 at 2:35 p.m. ET in New York, NY.
A webcast of the presentations will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.